Bioinformatics Analysis and Validation of the Role of Lnc-RAB11B-AS1 in the Development and Prognosis of Hepatocellular Carcinoma

Dedong Wang; Xiangzhi Hu; Jinbin Chen; Boheng Liang; Lin Zhang; Pengzhe Qin; Di Wu

doi:10.3390/cells11213517

Bioinformatics Analysis and Validation of the Role of Lnc-RAB11B-AS1 in the Development and Prognosis of Hepatocellular Carcinoma

Cells. 2022 Nov 6;11(21):3517. doi: 10.3390/cells11213517.

Authors

Dedong Wang^{1

2

3}, Xiangzhi Hu³, Jinbin Chen⁴, Boheng Liang^{1

2}, Lin Zhang^{1

2}, Pengzhe Qin^{1

2}, Di Wu^{1

2}

Affiliations

¹ Guangzhou Center for Disease Control and Prevention, Guangzhou 510440, China.
² Institute of Public Health, Guangzhou Medical University & Guangzhou Center for Disease Control and Prevention, Guangzhou 510440, China.
³ Department of Public Health and Preventive Medicine, School of Medicine, Jinan University, Guangzhou 510632, China.
⁴ Guangzhou Key Laboratory for Clinical Rapid Diagnosis and Early Warning of Infectious Diseases, KingMed School of Laboratory Medicine, Guangzhou Medical University, Guangzhou 510180, China.

Abstract

Lnc-RAB11B-AS1 is reported to be dysregulated in several types of cancers and can function as both an oncogene and tumor suppressor gene. To evaluate the potential role of lnc-RAB11B-AS1 in hepatocellular carcinoma (HCC), we investigated and evaluated its expression in HCC based on the data mining of a series of public databases, including TCGA, GEO, ICGC, HPA, DAVID, cBioPortal, GeneMIANA, TIMER, and ENCORI. The data showed downregulation of lnc-RAB11B-AS1 in HCC and was accompanied by the synchronous downregulation of the targeted RAB11B mRNA and its protein. Low expression of lnc-RAB11B-AS1 was associated with shorter overall survival (OS) and disease-free survival (DFS) of HCC patients, PD1/PD-L1 was correlated with low expression of RAB11B. Furthermore, Gene Ontology (GO) functional annotation and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis showed a correlation between immune cell change and non-alcoholic fatty liver disease. The above findings revealed that lnc-RAB11B-AS1 was down-regulated in HCC and closely associated with the clinical stage of the HCC patients, suggesting that lnc-RAB11B-AS1 could be a possible predictor for HCC and a potential new therapeutic target for the treatment of HCC.

Keywords: RAB11B; hepatocellular carcinoma (HCC); lnc-RAB11B-AS1; prognosis.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Carcinoma, Hepatocellular* / pathology
Computational Biology
Gene Expression Regulation, Neoplastic
Humans
Liver Neoplasms* / pathology
RNA, Long Noncoding* / genetics
RNA, Long Noncoding* / metabolism

Substances

RNA, Long Noncoding

Grants and funding

This work was funded by the Natural Science Foundation of China (81803325), Natural Science Foundation of Guangdong (2021A1515011175), Guangzhou Science and Technology Project (202102080126), The Key Project of Medicine Discipline of Guangzhou (2021-2023-12), Basic Research Project of Key Laboratory of Guangzhou (202102100001).